To evaluate the safety and efficacy of transcatheter aortic valve replacement with CoreValve bioprothesis in patients with severe aortic stenosis in high and intermediate surgical risk. Methods and results. Data was prospectively collected from 81 patients with severe aortic stenosis, who underwent CoreValve implantation in one centre. After risk stratification 38 patients (46.9%) were at high risk (STS score >8%). In 43 cases (53.1%) patients were at intermediate STS score (STS score >3 and <8%), but due to different coexisting characteristics patients were not candidates for surgery. Technical success was achieved in all cases. All-cause hospital mortality was 6.2% (5 cases) generally, without statistical difference between two groups (10.5% in high risk group, 4 patients; 2.3% in intermediate group, 1 patient). In two patients post-operation period was complicated by stroke (1 minor stroke, 1 major stroke; 2.5±1.7% of cases); in one case acute myocardial infarction developed 6 hours post CoreValve implantation (1.2%); in one case acute renal failure developed, leading to death of the patient. No significant differences in cerebrovascular accidents and myocardial infarction between the different risk groups were observed throughout hospital period. During three years 56 patients (72±5,0%) were available for follow up. Two patients died during follow-up: one patient died due to cancer progression (23 months after the implantation), one due to progression of chronic kidney insufficiency (18 months after implantation). No cerebrovascular or cardiac accidents were observed during follow up period. Conclusion. In selected patients with intermediate surgical risk TAVR procedure with the use of CoreValve system have good clinical outcomes in hospitalisation period and long-term follow-up.
Introduction
A ortic stenosis is the most common valvular heart disease, which affects 2-4% of individuals older 65 years in USA and performs 43% of all valvular heart diseases in Europe 1 . Aortic stenosis increase in incidence with age, so one in eight people over the age of 75 have moderate to severe aortic valve disease 2 . Regarding the population aging, this condition becomes a serious public health problem. Medical management of severe aortic stenosis is a suboptimal strategy, may provide temporary symptom re-lief but is not effective long term 3 . Surgical aortic valve replacement is a gold standard recommended treatment, but patients with severe symptoms have been found to have a significantly higher operative mortality than those with no or only mild symptoms 4 . The use of a bioprosthetic valves can be an opportunity in treatment of elderly patients with severe stenosis (<0.6 cm 2 ) or severe left ventricular dysfunction [5] [6] . Approximately 30% of the patients with severe symptoms and coexisting conditions are not candidates for surgery [7] [8] [9] . Endovascular treatment of severe aortic stenosis -transcatheter aortic valve replacement (TAVR) proved to be Abbreviations BMI = body mass index; CT = computer tomography; PCI = percutaneous coronary intervention; STS = Society of Thoracic Surgeons; TAVR = transcatheter aortic valve replacement; TEE = transesophageal echocardiography effective and safe treatment in a group of inoperable and high-risk for surgery operation patients [10] [11] [12] since 2002, when the procedure was first performed [13] [14] . Patients, undergoing TAVR procedure usually in advanced age, with serious comorbidity conditions (Logistic Euro-SCORE> 20%), and with contra indications to open surgery [15] [16] [17] [18] . 30-days mortality rate is reported on 5-20% level; myocardial infarction observed in 2-11% of cases, stroke in 3-9%, other vascular complications in 10-15% and AV-block in 4-30% of the patients. Mild to moderate paravalvular aortic valve regurgitation is present almost in half of the patients. The survival rate for 1 year with the use of transfemoral approach is 80-90% [19] [20] .
Bioprosthesys CoreValve (Medtronic, USA) is a representative of third generation of artificial aortic valves for endovascular implantation. It is manufactured by suturing 3 valve leaflets and a skirt, made from a single layer of porcine pericardium, onto a self-expanding, multi-level, radiopaque frame made of Nitinol. It can be implanted from femoral, left subclavian, axillar approach. TAVR procedure with CoreValve system is performed in cathlab or hybrid room, by physicians who have received Medtronic CoreValve TM training, under TEE guidance and under general anesthesia.
The aim of the study is clinical-functional analysis of immediate and long-term results of TAVR with the use of CoreValve transcatheter aortic valve in patients with severe aortic stenosis at high and intermediate surgical risk as defined by a Society of Thoracic Surgeons (STS) risk score 21 .
Methods
Data was prospectively collected in the period 2011-2014 from 81 TAVR cases on the base of cardio-vascular center of Regional Clinical Hospital. Patients had severe aortic stenosis and cardiac symptoms for whom conventional surgery to replace the aortic valve was associated with high risk, or low risk in combination with contraindications for surgery. Two patients (2.5%) had additional severe aortic regurgitation. In four cases combined valve disease was present: severe aortic stenosis and mild mitral stenosis. Two patients had relative contra indication for TAVR procedure -bicuspid aortic valve. All patients underwent precise evaluation for TAVR procedure with the use of CT angiography, echocardiography (transesophageal echo was used, if visualization on transthoracic echo was not appropriate), aortography in selected cases. Risk for surgical procedure was evaluated using STS risk score. Decision to a transcatheter or surgical strategy was made by heart team, that includes interventional cardiologist, cardiac surgeon, anesthesiologist and additional specialists in the case of pertinent comorbidities (nephrologist, endocrinologist). Written informed consent was obtained in all cases prior to the procedures.
In our center all TAVR cases are performed under general anesthesia, under TEE guidance during all the procedure.
All procedures were performed with transfemoral access. Four patients underwent access site closure with the Perclose device (Abbott Vascular Devices, Santa Clara, CA, USA) using pre-closure technique. In 77 cases standard arterial surgical cut-down was used, due to calcification (48 patients) and obesity (28 patients with BMI>30). According to the standard recommendations at the time of the procedure, patients were treated with 100 mg of acetylsalicylic acid, a 600 mg loading dose of clopidogrel, and unfractionated heparin 70-100 U/kg.
After TAVR procedure patients were followed up at 1, 6, 12 months and once a year after 12th months by means of a clinical visit or a standardized telephone interview. In the case of necessity additional hospital visit was administrated. Control TTE was performed every 6 months after the CoreValve implantation to assess valve functi on, peri-device flow and general echo parameters.
Results
All 81 patients were available for follow-up. Technical success was achieved in all cases. After risk stratification 38 patients (46.9%) were at high risk (STS score >8%). In 43 cases (53.1%) patients were at intermediate STS score (STS score >3 and <8%), but due to different coexisting characteristics patients were not candidates for surgery (Table 1) . Patients in high risk group were significantly older, with lower body mass index, but in both groups prevalence of arterial hypertension was very high (>95%) (Table 2). Significant symptoms of heart failure (NYHA III-IV) were prevalent in high risk group (76.3% vs. 34.9%, p=0.03). Chronic obstructive pulmonary disease and renal failure were also more prevalent in high risk patients. In past medical history there was no difference in frequency of myocardial infarction, coronary arteries interventions between two groups, but high risk patients had more previous strokes (31.6% vs. 4 26 , 40 patients in both groups). The decision about the time of the revascularisation (simultaneous or staged procedure) was made individually in every patient, considering the significance of lesion and clinical condition. In 82.5% (33 patients) -PCI was performed at the time of diagnostic (ad-hock procedure) or before 1 month-2 weeks before planned TAVR, and in 17.5% of cases (7 patients) simultaneous PCI and TAVR was performed.
Post TAVR-need for permanent pacemaker was at the same for both groups -in 9 patients in high risk group (23.7%), in 10 patients in intermediate group (23.3%, p=0.58).
All-cause hospital mortality was 6.2% (5 cases) generally, without statistical difference between two groups, probably due to the small amount of patients (10.5% in high risk group, 4 patients; 2.3% in intermediate group, 1 patient). In two patients post-operation period was complicated by stroke (1 minor stroke, 1 major stroke; 2.5±1.7% of cases); in one case acute myocardial infarction developed 6 hours post CoreValve implantation (1.2%); in one case acute renal failure developed, leading to death of the patient. No significant differences in cerebrovascular accidents and myocardial infarction between the different risk groups were observed throughout hospital period. During three years 56 patients (72±5,0%) were available for follow up. Two patients died during follow-up: one patient died due to cancer progression (23 months after the implantation), one due to progression of chronic kidney insufficiency (18 months after implantation). No cere-brovascular or cardiac accidents were observed during follow up period.
Discussion
The performed analysis is based on a single-centre experience with patients undergoing TAVR in high and intermediate surgical risks, with the use of CoreValve selfexpanding system. All patients, included in analysis, were precisely discussed by heart team of our multidisciplinary hospital. The risk for surgical aortic valve replacement was counted with the use of STS score, as the most exact predictor of outcome, as it was recognised, that the logistic EuroSCORE overestimates the risk for adverse clinical outcomes 22 . In big randomized trials, such as SURTAVI, STS score was chosen for risk evaluation of the patients 23 . Several conditions, such as porcelain aorta, chest wall irradiation or deformation, frailty making intermediate and low surgical patients contra-indicated for surgery. These factors are always discussed by a heart team, for choosing the appropriate treatment strategy. According to contemporary practice in Europe 24 , intermediate risk patients were included to our analysis. In several singlecentre and multi-centre studies patients in low surgical risks were also included [24] [25] .
All cause death in our centre was 6.2% for all patients, which is similar to analysis, performed by Wenaweser et. al. 26 , where all cause death was 6.4%. But in these study, patients were divided in three 
